Ambry Genetics Reaffirms Status as Worldwide Leader in Hereditary Cancer Testing with New Renal, Pancreatic and PGL-PCC Panels

August 01, 2013

FOR IMMEDIATE RELEASE

Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, the worldwide leader in hereditary cancer testing, announced today that it has officially launched its next-generation sequencing (NGS) renal, pancreatic and paraganglioma-pheochromocytoma (PGL/PCC) hereditary cancer panels.

Ambry Genetics was the first commercial laboratory to launch hereditary cancer panels using NGS in 2012 with their comprehensive BreastNext, OvaNext, ColoNext and CancerNext products. With hundreds of clinics and institutions utilizing these panels, Ambry has established itself as the scientific leaders in multi-gene cancer panel testing.

“As of today, Ambry Genetics continues to offer the most comprehensive hereditary cancer testing available,” said Elizabeth Chao, MD, Chief Medical Officer of Ambry Genetics. “As one example, pancreatic cancer is one of the deadliest and most incurable forms of the disease. Our test analyzes 13 genes simultaneously, and identifying a mutation in any one of those genes can lead to treatment options, including prevention. That’s what this type of genetic testing can offer.”

Ambry’s new offerings include an 18 gene renal cancer panel (RenalNext), 13 gene pancreatic cancer panel (PancNext) and 10 gene PGL/PCC panel (PGLNext). Previously, many of the genes on these panels could be ordered individually using traditional Sanger sequencing. The introduction of Ambry’s new NGS panel offerings allows all causative genes to be tested concurrently, saving time and money.

“I can’t imagine a more exhilarating place to be right now,” said AJ Stuenkel, Cancer Certified Genetic Counselor at Ambry Genetics. “Ambry is buzzing with excitement and a sense of purpose as we embrace recent scientific advances and continue to introduce novel testing options at an unmatched pace.”